Boundless Bio Inc. Common Stock (BOLD)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Boundless Bio as a Graham-style analyst: this is a clinical-stage oncology company with no revenue and no earnings history, so the numbers must carry the argument. The business has 28 employees and a lead candidate, BBI-940, in Phase 1/2 for breast cancers; the scientific premise around extrachromosomal DNA may be promising, but an early trial is not a durable moat. I cannot identify pricing power, recurring revenue, or a proven competitive advantage today. Financial health is the red flag. In fiscal 2025, the company reported a net loss of $58.2 million, after a $65.4 million loss in fiscal 2024 and a $49.4 million loss in fiscal 2023. In the quarter ended 2026-06-30, the net loss was $23.7 million, wider than the $15.7 million loss in the quarter ended 2025-06-30. FairStock calculates trailing free cash flow at -$56.7 million and an FCF yield of -102.6%. It also shows a Piotroski F-Score of 0/9, Altman Z-Score of -0.30, and a negative P/E of -0.85, while the P/B is 0.83 and D/E is 0.50 at the 2026-10-13 close. FairStock's Lynch category is 'none' because of losses in each of the last three years. At $2.43, the market cap is $55.3 million. The low price-to-book might look interesting, but book value can be consumed by cash burn. With profit growth of -51.15% and no revenue, this is a speculative option on clinical data, not a value investment with a margin of safety.

In plain English: Boundless Bio is a small clinical-stage cancer drug company. It has no product revenue and has lost money every year, with cash spending far above what it brings in. Because there are no profits, the stock is hard to value on normal business numbers; the low price compared with accounting net worth may look interesting, but the company is still a risky early-stage bet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer